AbbVievsADMA Biologics

ABBV and ADMA stock compared: price, dividend, valuation and results, from SEC filings.

ADMA

ADMA Biologics Inc

$13.68

Value $3.0B

+3.32%
ADMA's page

AbbVie (ABBV) has a market value of $522B and ADMA Biologics (ADMA) $3.0B. Over the last year, with dividends, ABBV moved +30.3% and ADMA -16.9%. The P/E is 50.7 for ABBV and 16.6 for ADMA. Dividend yield: ABBV 2.35%, ADMA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    ADMA$3.0B

    ABBV is 172 times ADMA

  • Revenue, 12 months

    ABBV$66.0B

    ADMA$519M

    ABBV is 127 times ADMA

  • Net income, 12 months

    ABBV$10.3B

    ADMA$182M

    ABBV is 57 times ADMA

  • Operating margin

    ABBV32.2%

    ADMA46.5%

    14.3 points apart

  • ROIC

    ABBV25.7%

    ADMA32.6%

    6.9 points apart

  • P/E

    ABBV50.7

    ADMA16.6

    ABBV is 3.0 times ADMA

  • Dividend yield

    ABBV2.4%

    ADMA0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.5%

    ADMA+724.1%

    522.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.5%

ADMA+724.2%

0500100020222023202420252026
Returns by period
PeriodABBVWith dividendsADMAWith dividends
1 year since November 12, 2025+30.3%Price +26.5%-16.9%Price -16.9%
3 years since November 13, 2023+135.3%+33.0% a yearPrice +112.8%+265.8%+54.1% a yearPrice +265.8%
5 years since November 12, 2021+201.5%+24.7% a yearPrice +152.2%+724.1%+52.5% a yearPrice +724.1%
10 years since November 15, 2016+605.5%+21.6% a yearPrice +369.3%+116.1%+8.0% a yearPrice +116.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieADMAADMA Biologics

Valuation

ABBVADMA
Valuation
Price$295.03$13.68
Market value$522B$3.0B
Enterprise value (EV)$592B$3.1B
P/E50.716.6
P/E, 5-year median57.0–
P/B–6.9
EV/EBIT27.912.9
Free cash flow yield3.6%4.4%

Results and growth

ABBVADMA
Results and growth
Revenue, 12 months$66.0B$519M
Net income, 12 months$10.3B$182M
Free cash flow, 12 months$18.9B$133M
Earnings per share, 12 months$5.81$0.77
Revenue growth, year on year8.6%19.6%
Revenue growth a year, past+5.9%over 5 years+64.6%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVADMA
Margins and returns on capital
Gross margin73.7%68.5%
Operating margin32.2%46.5%
Net margin15.7%35.1%
ROIC25.7%32.6%
ROE–42.5%

Balance sheet

ABBVADMA
Balance sheet
Cash$10.8B$125M
Total debt$80.9B$203M
Net debt / EBITDA3.20.3
Interest cover7.1×22.8×

Dividends and buybacks

ABBVADMA
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%1.1%
Shareholder yield2.5%1.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or ADMA

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or ADMA Biologics?

By market value, AbbVie ($522B) is about 171.9 times ADMA Biologics ($3.0B), at today's prices.

How did ABBV and ADMA stock do over the last 10 years?

Since November 15, 2016, ABBV's price moved +369.3% and ADMA's +116.1%. With dividends: ABBV +605.5% (+21.6% a year), ADMA +116.1% (+8.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or ADMA?

The dividend yield at today's price is 2.35% for AbbVie and none for ADMA Biologics. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and ADMA?

At today's price, the P/E is 50.7 for ABBV and 16.6 for ADMA. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, AbbVie or ADMA Biologics?

Over the last twelve months, the net margin was 15.7% for AbbVie and 35.1% for ADMA Biologics, and the operating margin 32.2% and 46.5%. Revenue was $66.0B and $519M.

Which is the better investment, AbbVie or ADMA Biologics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.